403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
ValiSeek chief discusses upcoming clinical trials of lung cancer drug
(MENAFN- ProactiveInvestors)Suzanne Dilly the chief executive officer of ValiSeek a division life sciences firm ValiRx (LON:VAL) explains the company's deal with Clinical Accelerator to carry out the work on a Phase IIB study for lung cancer treatment VAL 401. The drug is being developed through a joint venture with Tangent Profiling to target patients with non-small-cell lung adenocarcinoma the most common form of the disease.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment